Abstract
A potential application of embryonic and inducible pluripotent stem cells for the therapy of degenerative diseases involves pure somatic cells, free of tumorigenic undifferentiated embryonic and inducible pluripotent stem cells. In complex collections of chemicals with pharmacological potential we expect to find molecules able to induce specific pluripotent stem cell death, which could be used in some cell therapy settings to eliminate undifferentiated cells. Therefore, we have screened a chemical library of 1120 small chemicals to identify compounds that induce specifically apoptotic cell death in undifferentiated mouse embryonic stem cells (ESCs). Interestingly, three compounds currently used as clinically approved drugs, nortriptyline, benzethonium chloride and methylbenzethonium chloride, induced differential effects in cell viability in ESCs versus mouse embryonic fibroblasts (MEFs). Nortriptyline induced apoptotic cell death in MEFs but not in ESCs, whereas benzethonium and methylbenzethonium chloride showed the opposite effect. Nortriptyline, a tricyclic antidepressant, has also been described as a potent inhibitor of mitochondrial permeability transition, one of two major mechanisms involved in mitochondrial membrane permeabilization during apoptosis. Benzethonium chloride and methylbenzethonium chloride are quaternary ammonium salts used as antimicrobial agents with broad spectrum and have also been described as anticancer agents. A similar effect of benzethonium chloride was observed in human induced pluripotent stem cells (hiPSCs) when compared to both primary human skin fibroblasts and an established human fibroblast cell line. Human fibroblasts and hiPSCs were similarly resistant to nortriptyline, although with a different behavior. Our results indicate differential sensitivity of ESCs, hiPSCs and fibroblasts to certain chemical compounds, which might have important applications in the stem cell-based therapy by eliminating undifferentiated pluripotent stem cells from stem cell-derived somatic cells to prevent tumor formation after transplantation for therapy of degenerative diseases.
References
Keller, G. (2005). Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes and Development, 19, 1129–1155.
Brustle, O., Jones, K. N., Learish, R. D., et al. (1999). Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science, 285, 754–756.
McDonald, J. W., Liu, X. Z., Qu, Y., et al. (1999). Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nature Medicine, 5, 1410–1412.
Klug, M. G., Soonpaa, M. H., Koh, G. Y., & Field, L. J. (1996). Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. Journal of Clinical Investigation, 98, 216–224.
Min, J. Y., Yang, Y., Converso, K. L., et al. (2002). Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. Journal of Applied Physiology, 92, 288–296.
Soria, B., Roche, E., Berna, G., Leon-Quinto, T., Reig, J. A., & Martin, F. (2000). Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes, 49, 157–162.
Pedersen, R. A. (1994). Studies of in vitro differentiation with embryonic stem cells. Reproduction, Fertility and Development, 6, 543–552.
Odorico, J. S., Kaufman, D. S., & Thomson, J. A. (2001). Multilineage differentiation from human embryonic stem cell lines. Stem Cells, 19, 193–204.
Stockwell, B. R. (2000). Chemical genetics: ligand-based discovery of gene function. Nature Reviews Genetics, 1, 116–125.
Thorpe, D. S. (2003). Forward and reverse chemical genetics using SPOS-based combinatorial chemistry. Combinatorial Chemistry and High Throughput Screening, 6, 623–647.
Sachinidis, A., Sotiriadou, I., Seelig, B., Berkessel, A., & Hescheler, J. (2008). A chemical genetics approach for specific differentiation of stem cells to somatic cells: a new promising therapeutical approach. Combinatorial Chemistry and High Throughput Screening, 11, 70–82.
Evans, M. J., & Kaufman, M. H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature, 292, 154–156.
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282, 1145–1147.
Gissel, C., Voolstra, C., Doss, M. X., et al. (2005). An optimized embryonic stem cell model for consistent gene expression and developmental studies: a fundamental study. Thrombosis and Haemostasis, 94, 719–727.
Wei, M. C., Zong, W. X., Cheng, E. H., et al. (2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science, 292, 727–730.
Bennett, I. F. (1962). The constellation of depression: its treatment with nortriptyline. I. Criteria for true antidepressant activity. The Journal of Nervous and Mental Disease, 134, 561–565.
Stavrovskaya, I. G., Narayanan, M. V., Zhang, W., et al. (2004). Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. Journal of Experimental Medicine, 200, 211–222.
Egashira, T., Takayama, F., & Yamanaka, Y. (1996). Effects of long-term treatment with dicyclic, tricyclic, tetracyclic, and noncyclic antidepressant drugs on monoamine oxidase activity in mouse brain. General Pharmacology, 27, 773–778.
Wang, H., Guan, Y., Wang, X., et al. (2007). Nortriptyline delays disease onset in models of chronic neurodegeneration. European Journal of Neuroscience, 26, 633–641.
Zhang, W. H., Wang, H., Wang, X., et al. (2008). Nortriptyline protects mitochondria and reduces cerebral ischemia/hypoxia injury. Stroke, 39, 455–462.
Petronilli, V., Miotto, G., Canton, M., et al. (1999). Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophysical Journal, 76, 725–734.
Grimm, S., & Brdiczka, D. (2007). The permeability transition pore in cell death. Apoptosis, 12, 841–855.
Verrier, F., Deniaud, A., Lebras, M., et al. (2004). Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis. Oncogene, 23, 8049–8064.
Fox, D. A., Epstein, M. L., & Bass, P. (1983). Surfactants selectively ablate enteric neurons of the rat jejunum. Journal of Pharmacology and Experimental Therapeutics, 227, 538–544.
El-On, J., & Messer, G. (1986). Leishmania major: antileishmanial activity of methylbenzethonium chloride. American Journal of Tropical Medicine and Hygiene, 35, 1110–1116.
Yip, K. W., Mao, X., Au, P. Y., et al. (2006). Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. Clinical Cancer Research, 12, 5557–5569.
Nomura, Y., Bhawal, U. K., Nishikiori, R., Sawajiri, M., Maeda, T., & Okazaki, M. (2010). Effects of high-dose major components in oral disinfectants on the cell cycle and apoptosis in primary human gingival fibroblasts in vitro. Dental Materials Journal, 29, 75–83.
Conway, A. E., Lindgren, A., Galic, Z., et al. (2009). A self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cell-derived tumors. Stem Cells, 27, 18–28.
Andrews, P. W., Damjanov, I., Simon, D., & Dignazio, M. (1985). A pluripotent human stem-cell clone isolated from the TERA-2 teratocarcinoma line lacks antigens SSEA-3 and SSEA-4 in vitro, but expresses these antigens when grown as a xenograft tumor. Differentiation, 29, 127–135.
Hanaoka, K., Hayasaka, M., Noguchi, T., & Kato, Y. (1991). The stem cells of a primordial germ cell-derived teratocarcinoma have the ability to form viable mouse chimeras. Differentiation, 48, 83–87.
Tsai, R. Y., & McKay, R. D. (2002). A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes and Development, 16, 2991–3003.
Nikpour, P., Mowla, S. J., Jafarnejad, S. M., Fischer, U., & Schulz, W. A. (2009). Differential effects of Nucleostemin suppression on cell cycle arrest and apoptosis in the bladder cancer cell lines 5637 and SW1710. Cell Proliferation, 42, 762–769.
Acknowledgements
We thank Jesús Martínez de la Fuente, from the Instituto de Nanociencia de Aragón, for access to the inverted fluorescence microscope. This work was funded by grants from the Aragon Institute of Health Sciences to J. Sancho (PIPAMER07/02) and to J. A. Carrodeguas (PIPAMER08/17, PIPAMER09/13 and PIPAMER10/009); from the University of Zaragoza to J. A. Carrodeguas (UZ2010-BIO-03); from the Ministerio de Educación y Ciencia to J. A. Carrodeguas (BFU2006-07026); from the Ministerio de Ciencia e Innovación to J. Sancho (PI078/08 and BFU2010-16297) and to J. A. Carrodeguas (BFU2009-11800). The contribution by C. Antzelevitch and MX. Doss was supported by grant HL47678 (CA) from NHLBI, and grants from NYSTEM (CA), AHA National Scientist Development grant (MXD) and New York State and Florida Masons. C. Conesa is a postdoctoral fellow funded by the Programa Aragonés de Medicina Regenerativa (PAMER) and by the Institute of Biocomputation and Physics of Complex Systems.
Conflicts of interest
The authors declare no potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Conesa, C., Doss, M.X., Antzelevitch, C. et al. Identification of Specific Pluripotent Stem Cell Death—Inducing Small Molecules by Chemical Screening. Stem Cell Rev and Rep 8, 116–127 (2012). https://doi.org/10.1007/s12015-011-9248-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12015-011-9248-4